Highlights in European Radiology newsletter recently featured the collaborative work of Professor @anantm, Lin Li, PhD candidate, and others. "Correlation between MRI phenotypes and a genomic classifier of prostate cancer" https://t.co/Kd0oJfbDZV @ESR_Sci
RT @ESR_SciPub: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient managemen…
RT @CCIPD_Case: "Highlights in #EuropeanRadiology" features the collaborative work of @CCIPD_Case @anantm, Lin Li and others. @CaseEngineer…
"Highlights in #EuropeanRadiology" features the collaborative work of @CCIPD_Case @anantm, Lin Li and others. @CaseEngineer @CWRUBME @cwru @CWRUSOM @caseccc
RT @ESR_SciPub: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient managemen…
RT @ESR_SciPub: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient managemen…
RT @ESR_SciPub: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient managemen…
Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient management. It seems that visibility with MRI is a prognostic predictor. #EuropeanRadiology Click to learn more: https://t.co/0eiqyNl4JT http
RT @myESR: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient management. It…
RT @myESR: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient management. It…
RT @CCIPD_Case: Thrilled to have been part of this exciting work with @purysko @EricKleinMD @anantm and others. https://t.co/az7qeboc6C
Thrilled to have been part of this exciting work with @purysko @EricKleinMD @anantm and others.
RT @myESR: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient management. It…
RT @myESR: Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient management. It…
Defining which #ProstateCancers are potentially aggressive and provide early #metastases is essential for patient management. It seems that visibility with #MRI is a prognostic predictor. Click below to learn more. #radiology https://t.co/sP4lNmxbNE
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
@M_FerrandinoMD But... https://t.co/dAHDTft55E We have a ways to go to justify the added costs. MRI much more expensive here than UK. I remember Dr. Emberton saying MRI was only $400 to $500 in UK.
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
Interesting data. Are these MR-invisible lesions positive on molecular imaging like PSMA PET? This could explain the apparent detection superiority of PSMA compared do mpMR.
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
RT @EricKleinMD: Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data…
Further data that ~15% of MR-invisible lesions have molec features of aggressive CaP https://t.co/APtKjIDscl. Along w/data from UCLA https://t.co/wToZSnTnPG & Mt Sinai https://t.co/IBo76A2xKh strong evidence that molec changes occur 1st, then histology
RT @purysko: Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. https://t.co/8m0YQ1Tvf4…
MRI visible prostate lesions have more aggressive genetics features than MRI invisible lesions. Does this mean an MRI targeted biopsy is enough? https://t.co/dFCMZvvKaw
RT @CCIPD_Case: Thrilled to be part of this very important collaboration - #radiogenomics for #prostatecancer. @anantm @CCIPD_Case @cwru @C…
RT @purysko: Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. https://t.co/8m0YQ1Tvf4…
RT @purysko: Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. https://t.co/8m0YQ1Tvf4…
RT @CCIPD_Case: Thrilled to be part of this very important collaboration - #radiogenomics for #prostatecancer. @anantm @CCIPD_Case @cwru @C…
RT @CCIPD_Case: Thrilled to be part of this very important collaboration - #radiogenomics for #prostatecancer. @anantm @CCIPD_Case @cwru @C…
RT @CCIPD_Case: Thrilled to be part of this very important collaboration - #radiogenomics for #prostatecancer. @anantm @CCIPD_Case @cwru @C…
Thrilled to be part of this very important collaboration - #radiogenomics for #prostatecancer. @anantm @CCIPD_Case @cwru @CWRUBME @CWRUSOM @caseccc @CaseEngineer
RT @purysko: Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. https://t.co/8m0YQ1Tvf4…
RT @purysko: Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. https://t.co/8m0YQ1Tvf4…
Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. https://t.co/8m0YQ1Tvf4 Thank you @ESR_SciPub !